PIK3CA and cancer: Song et al profiled a selection of PI3K inhibitors for biochemical activity and pharmacokinetic properties and discovered that taselisib and inavolisib showed increased mutant potency in cell viability assays in a cancer cell line panel compared with other PI3K inhibitors.72